Scientists have found a promising new treatment for Parkinson's disease

Researchers from Israel's Ben Gurion University (BGU) have found that protein BMP5/7 promises to provide a new approach to the treatment of Parkinson's disease, which is expected to slow or stop the progression of the disease, according to a recent study published in Brain.
is a common neurological degenerative disease, common in the elderly, the average age of onset is about 60 years old, under 40 years of age, parkinson's disease is less common in young people.
prevalence of Parkinson's disease among people over 65 years of age in china is about 1.7%.
of parkinson's disease patients are distributed cases, and less than 10 percent have a family history.
, Parkinson's disease has affected more than 10 million people worldwide.
is caused by the degenerative degeneration of dopamine-producing brain cells, leading to tremors and severe movement disorders.
studies have shown that proteins α-synaptic nucleoproteins present in the human brain fold incorrectly in these cells and form toxic lumps, leading to disease.
the current treatment of Parkinson's disease can improve symptoms, but the treatment effect for the late stage of the disease is not ideal, can not slow down or cure the disease.
Claude Brodski, director of the BGU Molecular Neuroscience Laboratory, found that BMP5/7 signals in neurons significantly decreased in brain cells that produce dopamine, which may speed up the progression of Parkinson's disease.
, the researchers built a mouse model based on viral vectors.
they found that in mouse models of Parkinson's disease, treatment targeting BMP5/7 was effective in preventing movement disorders caused by the accumulation of α-synthesia nucleoproteins and reversing the loss of brain cells that produced dopamine.
Brodski said: "These findings are promising because they suggest that targeting BMP5/7 can slow or stop the onset of Parkinson's disease.
now, we are working to bring these findings closer to clinical use.
, BGN Technologies, a technology transfer company at Ben Gurrian University, has filed several patent applications for this breakthrough.
, senior vice president of business development at BGN Technologies Biopharmaceuticals, said: "There is a huge demand for new treatments for Parkinson's disease, especially in the advanced stages of the disease.
Brodski's findings, while still in their early stages, provide a target for disease-modifying drugs, and we are now looking for an industry partner to further develop the patent-pending invention.
”(）